Erratum: Cancer cells that survive radiation therapy acquire HIF-1 activity and translocate toward tumour blood vessels (Nature Communications (2012) 3 (783) doi: 10.1038/ncomms1786);Cancer cells that survive radiation therapy acquire HIF-1 activity and translocate towards tumour blood vessels

Nature Communications

Volumn 3, Issue , 2012, Pages

  Harada, Hiroshi ^a   Inoue, Masahiro ^b   Itasaka, Satoshi ^a   Hirota, Kiichi ^c   Morinibu, Akiyo ^a   Shinomiya, Kazumi ^a   Zeng, Lihua ^a,d   Ou, Guangfei ^a   Zhu, Yuxi ^a   Yoshimura, Michio ^a,e   McKenna, W Gillies ^e   Muschel, Ruth J ^e   Hiraoka, Masahiro ^a  

^a KYOTO UNIVERSITY   (Japan)

^b OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

^c KYOTO UNIVERSITY HOSPITAL   (Japan)

^d FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^e UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD VESSEL; CANCER CELL CULTURE; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CELL FATE; CELL HYPOXIA; CELL SURVIVAL; CONTROLLED STUDY; HUMAN; HUMAN CELL; IRRADIATION; MOUSE; NONHUMAN; REOXYGENATION; TUMOR BLOOD VESSEL; ANIMAL; BAGG ALBINO MOUSE; CELL MOTION; CYTOLOGY; DRUG SCREENING; MALE; METABOLISM; NEOPLASM; PATHOPHYSIOLOGY; RADIATION DOSE; RADIATION EXPOSURE; TUMOR CELL CULTURE; TUMOR CELL LINE; VASCULARIZATION;

ANIMALS; CELL HYPOXIA; CELL LINE, TUMOR; CELL MOVEMENT; CELL SURVIVAL; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1; MALE; MICE; MICE, INBRED BALB C; NEOPLASMS; RADIATION TOLERANCE; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84860294684     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms1786     Document Type: Erratum

References (52)

1. Hanahan, D. & Weinberg, R. A. The hallmarks of cancer. Cell 100, 57-70 (2000). (Pubitemid 30046295)
2. Thomlinson, R. H. & Gray, L. H. The histological structure of some human lung cancers and the possible implications for radiotherapy. Br. J. Cancer 9, 539-549 (1955).
3. Vaupel, P., Kallinowski, F. & Okunieff, P. Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. Cancer Res. 49, 6449-6465 (1989). (Pubitemid 20008770)
4. Vaupel, P., Hockel, M. & Mayer, A. Detection and characterization of tumor hypoxia using pO2 histography. Antioxid. Redox Signal. 9, 1221-1235 (2007). (Pubitemid 47080831)
5. Vaupel, P., Schlenger, K., Knoop, C. & Hockel, M. Oxygenation of human tumors: evaluation of tissue oxygen distribution in breast cancers by computerized O2 tension measurements. Cancer Res. 51, 3316-3322 (1991).
6. Kennedy, A. S. et al. Proliferation and hypoxia in human squamous cell carcinoma of the cervix: first report of combined immunohistochemical assays. Int. J. Radiat. Oncol. Biol. Phys. 37, 897-905 (1997). (Pubitemid 27181324)
7. Kizaka-Kondoh, S., Inoue, M., Harada, H. & Hiraoka, M. Tumor hypoxia: a target for selective cancer therapy. Cancer Sci. 94, 1021-1028 (2003). (Pubitemid 38035514)
8. Brown, J. M. & Wilson, W. R. Exploiting tumour hypoxia in cancer treatment. Nat. Rev. Cancer 4, 437-447 (2004). (Pubitemid 38745529)
9. Kimura, H. et al. Fluctuations in red cell flux in tumor microvessels can lead to transient hypoxia and reoxygenation in tumor parenchyma. Cancer Res. 56, 5522-5528 (1996). (Pubitemid 27011389)
10. Wang, G. L., Jiang, B. H., Rue, E. A. & Semenza, G. L. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc. Natl Acad. Sci. USA 92, 5510-5514 (1995).
11. Berra, E., Roux, D., Richard, D. E. & Pouyssegur, J. Hypoxia-inducible factor-1 alpha (HIF-1 alpha) escapes O(2)-driven proteasomal degradation irrespective of its subcellular localization: nucleus or cytoplasm. EMBO Rep. 2, 615-620 (2001). (Pubitemid 32707709)
12. Jaakkola, P. et al. Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science 292, 468-472 (2001). (Pubitemid 32335942)
13. Semenza, G. L. Regulation of cancer cell metabolism by hypoxia-inducible factor 1. Semin. Cancer Biol. 19, 12-16 (2009).
14. Chan, D. A. & Giaccia, A. J. Hypoxia, gene expression, and metastasis. Cancer Metastasis Rev. 26, 333-339 (2007).
15. Sullivan, R. & Graham, C. H. Hypoxia-driven selection of the metastatic phenotype. Cancer Metastasis Rev. 26, 319-331 (2007). (Pubitemid 47101665)
16. Forsythe, J. A. et al. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol. Cell. Biol. 16, 4604-4613 (1996). (Pubitemid 26272112)
17. Liao, D. & Johnson, R. S. Hypoxia: a key regulator of angiogenesis in cancer. Cancer Metastasis Rev. 26, 281-290 (2007). (Pubitemid 47101669)
18. Deschner, E. E. & Gray, L. H. Influence of oxygen tension on x-ray-induced chromosomal damage in Ehrlich ascites tumor cells irradiated in vitro and in vivo. Radiat. Res. 11, 115-146 (1959).
19. Gray, L. H., Conger, A. D., Ebert, M., Hornsey, S. & Scott, O. C. The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy. Br. J. Radiol. 26, 638-648 (1953).
20. Moeller, B. J., Cao, Y., Li, C. Y. & Dewhirst, M. W. Radiation activates HIF-1 to regulate vascular radiosensitivity in tumors: role of reoxygenation, free radicals, and stress granules. Cancer Cell 5, 429-441 (2004). (Pubitemid 38610245)
21. Moeller, B. J. & Dewhirst, M. W. Raising the bar: how HIF-1 helps determine tumor radiosensitivity. Cell Cycle 3, 1107-1110 (2004). (Pubitemid 40268623)
22. Moeller, B. J. & Dewhirst, M. W. HIF-1 and tumour radiosensitivity. Br. J. Cancer. 95, 1-5 (2006). (Pubitemid 43980546)
23. Moeller, B. J., Richardson, R. A. & Dewhirst, M. W. Hypoxia and radiotherapy: opportunities for improved outcomes in cancer treatment. Cancer Metastasis Rev. 26, 241-248 (2007). (Pubitemid 47101661)
24. Bussink, J., Kaanders, J. H. & van der Kogel, A. J. Tumor hypoxia at the micro-regional level: clinical relevance and predictive value of exogenous and endogenous hypoxic cell markers. Radiother. Oncol. 67, 3-15 (2003). (Pubitemid 36575463)
25. Moon, E. J., Brizel, D. M., Chi, J. T. & Dewhirst, M. W. The potential role of intrinsic hypoxia markers as prognostic variables in cancer. Antioxid. Redox Signal. 9, 1237-1294 (2007). (Pubitemid 47080832)
26. Kizaka-Kondoh, S., Tanaka, S., Harada, H. & Hiraoka, M. The HIF-1-active microenvironment: an environmental target for cancer therapy. Adv. Drug Deliv. Rev. 61, 623-632 (2009).
27. Sobhanifar, S., Aquino-Parsons, C., Stanbridge, E. J. & Olive, P. Reduced expression of hypoxia-inducible factor-1alpha in perinecrotic regions of solid tumors. Cancer Res. 65, 7259-7266 (2005). (Pubitemid 41161257)
28. Kizaka-Kondoh, S. & Konse-Nagasawa, H. Significance of nitroimidazole compounds and hypoxia-inducible factor-1 for imaging tumor hypoxia. Cancer Sci. 100, 1366-1373 (2009).
29. Harada, H. et al. The Akt/mTOR pathway assures the synthesis of HIF-1alpha protein in a glucose- and reoxygenation-dependent manner in irradiated tumors. J. Biol. Chem. 284, 5332-5342 (2009).
30. Harada, H. et al. Treatment regimen determines whether an HIF-1 inhibitor enhances or inhibits the effect of radiation therapy. Br. J. Cancer. 100, 747-757 (2009).
31. Murata, R. et al. Reoxygenation after single irradiation in rodent tumors of different types and sizes. Int. J. Radiat. Oncol. Biol. Phys. 34, 859-865 (1996). (Pubitemid 26089224)
32. Feil, R., Wagner, J., Metzger, D. & Chambon, P. Regulation of Cre recombinase activity by mutated estrogen receptor ligand-binding domains. Biochem. Biophys. Res. Commun. 237, 752-757 (1997). (Pubitemid 27434760)
33. Indra, A. K. et al. Temporally-controlled site-specific mutagenesis in the basal layer of the epidermis: comparison of the recombinase activity of the tamoxifen-inducible Cre-ER(T) and Cre-ER(T2) recombinases. Nucleic Acids Res. 27, 4324-4327 (1999). (Pubitemid 29533170)
34. Metzger, D., Clifford, J., Chiba, H. & Chambon, P. Conditional site-specific recombination in mammalian cells using a ligand-dependent chimeric Cre recombinase. Proc. Natl Acad. Sci. USA 92, 6991-6995 (1995).
35. Harada, H. et al. The combination of hypoxia-response enhancers and an oxygen-dependent proteolytic motif enables real-time imaging of absolute HIF-1 activity in tumor xenografts. Biochem. Biophys. Res. Commun. 360, 791-796 (2007). (Pubitemid 47077390)
36. Dewhirst, M. W. Intermittent hypoxia furthers the rationale for hypoxia-inducible factor-1 targeting. Cancer Res. 67, 854-855 (2007).
37. Dewhirst, M. W. Relationships between cycling hypoxia, HIF-1, angiogenesis and oxidative stress. Radiat. Res. 172, 653-665 (2009).
38. Martinive, P. et al. Preconditioning of the tumor vasculature and tumor cells by intermittent hypoxia: implications for anticancer therapies. Cancer Res. 66, 11736-11744 (2006). (Pubitemid 46094185)
39. Li, F. et al. Regulation of HIF-1alpha stability through S-nitrosylation. Mol. Cell 26, 63-74 (2007). (Pubitemid 46550936)
40. Yeo, E. J. et al. YC-1: a potential anticancer drug targeting hypoxia-inducible factor 1. J. Natl Cancer Inst. 95, 516-525 (2003).
41. Lee, K. et al. Acriflavine inhibits HIF-1 dimerization, tumor growth, and vascularization. Proc. Natl Acad. Sci. USA 106, 17910-17915 (2009).
42. Higgins, D. F. et al. Hypoxia promotes fibrogenesis in vivo via HIF-1 stimulation of epithelial-to-mesenchymal transition. J. Clin. Invest. 117, 3810-3820 (2007). (Pubitemid 350224091)
43. Yang, M. H. et al. Direct regulation of TWIST by HIF-1alpha promotes metastasis. Nat. Cell Biol. 10, 295-305 (2008).
44. Dewhirst, M. W., Cao, Y. & Moeller, B. Cycling hypoxia and free radicals regulate angiogenesis and radiotherapy response. Nat. Rev. Cancer 8, 425-437 (2008). (Pubitemid 351744964)
45. Skala, M. C., Fontanella, A., Lan, L., Izatt, J. A. & Dewhirst, M. W. Longitudinal optical imaging of tumor metabolism and hemodynamics. J. Biomed. Opt. 15, 011112 (2010).
46. Box, A. H. & Demetrick, D. J. Cell cycle kinase inhibitor expression and hypoxia-induced cell cycle arrest in human cancer cell lines. Carcinogenesis 25, 2325-2335 (2004). (Pubitemid 39625172)
47. Gardner, L. B. et al. Hypoxia inhibits G1/S transition through regulation of p27 expression. J. Biol. Chem. 276, 7919-7926 (2001).
48. Bristow, R. G. & Hill, R. P. Hypoxia and metabolism. Hypoxia, DNA repair and genetic instability. Nat. Rev. Cancer 8, 180-192 (2008). (Pubitemid 351301853)
49. Chan, N. et al. Chronic hypoxia decreases synthesis of homologous recombination proteins to offset chemoresistance and radioresistance. Cancer Res. 68, 605-614 (2008). (Pubitemid 351380090)
50. Liu, J. et al. Real-time imaging of hypoxia-inducible factor-1 activity in tumor xenografts. J. Radiat. Res. (Tokyo) 46, 93-102 (2005). (Pubitemid 40780154)
51. Chen, C. & Okayama, H. High-efficiency transformation of mammalian cells by plasmid DNA. Mol. Cell. Biol. 7, 2745-2752 (1987).
52. Harada, H., Kizaka-Kondoh, S. & Hiraoka, M. Optical imaging of tumor hypoxia and evaluation of efficacy of a hypoxia-targeting drug in living animals. Mol. Imaging 4, 182-193 (2005). (Pubitemid 43143791)